Evaluation of the Cross-reactivity of Antidrug Antibodies to CT-P13 and Infliximab Reference Product (Remicade): An Analysis Using Immunoassays Tagged with Both Agents.

Document types check

Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/31855

Title:	Evaluation of the Cross-reactivity of Antidrug Antibodies to CT-P13 and Infliximab Reference Product (Remicade): An Analysis Using Immunoassays Tagged with Both Agents.
Authors:	Reinisch, Walter Jahnsen, Jørgen Schreiber, Stefan Danese, Silvio Panés, Julián Balsa, Alejandro Park, Won Kim, JiSoo Lee, Jee Un Yoo, Dae Hyun View more
Mesh:	Adolescent Adult Aged Antibodies Antibodies, Monoclonal Antirheumatic Agents Arthritis, Rheumatoid Biosimilar Pharmaceuticals Cross Reactions Humans Immunoassay Infliximab Middle Aged Spondylitis, Ankylosing Treatment Outcome Young Adult View more
Issue Date:	Jun-2017
Citation:	BioDrugs.2017 Jun;(31)3:223-237
Abstract:	During two pivotal clinical trials of the infliximab biosimilar CT-P13 (PLANETAS and PLANETRA), antidrug antibodies (ADAs) and neutralising antibodies (NAbs) were detected in the sera of patients treated with CT-P13 and the reference product (RP; Remicade).
PMID:	28497221
URI:	https://hdl.handle.net/20.500.12530/31855
Rights:	openAccess
Appears in Collections:	Fundaciones e Institutos de Investigación > IIS H. U. La Paz > Artículos

Files in This Item:

File	Description	Size	Format
PMC5443869.pdf		1.13 MB	Adobe PDF	View/Open